1


                                                                    EXHIBIT 99.1

FOR IMMEDIATE RELEASE

                                            
At Heska Corporation:                          At Noonan/Russo Communications, Inc.:
Ron Hendrick, Executive Vice President & CFO   Miriam Weber (Investor Relations)
     (970) 493-7272                                 (212) 696-4455, Ext. 352
Robert Grieve, Chairman & CEO                  Matthew Knight (Media Relations)
     (970) 493-7272                                 (212) 696-4455, Ext. 271



HESKA COMPLETES $5.7 MILLION PRIVATE PLACEMENT

Fort Collins, Colo.- February 7, 2001 - Heska Corporation (Nasdaq: HSKA)
announced today that it has completed a private placement of approximately 4.57
million shares of common stock for aggregate proceeds of approximately $5.7
million with a group of institutional investors, including existing stockholders
of Heska. Wells Fargo Van Kasper acted as a financial advisor with respect to
the transaction. Heska intends to use the proceeds for working capital.

The common stock sold to the investors has not been registered under the
Securities Act of 1933. Accordingly, these shares may not be offered or sold in
the United States, except pursuant to the effectiveness of a registration
statement or an applicable exemption from the registration requirements of the
Securities Act. Heska has agreed to file a registration statement covering
resales of these shares by the investors. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy the common
stock. This press release is being issued pursuant to and in accordance with
Rule 135c under the Securities Act.

Heska discovers, develops, manufactures and markets companion animal health
products, primarily for dogs, cats and horses. Heska has a sophisticated
scientific effort devoted to applying biotechnology to the large and growing
companion animal health market. Heska's existing state-of-the-art allergy
diagnostics and immunotherapy products are sold to veterinarians for the testing
and treatment of thousands of allergic cats and dogs each year. Heska also
offers diagnostic and patient monitoring instrumentation and supplies, as well
as pharmaceuticals, vaccines and diagnostic products in the United States and
Europe to veterinarians, and operates a USDA- and FDA- licensed facility, which
manufactures vaccines and pharmaceutical products. For additional information on
Heska and its products, visit the company's web site at www.heska.com.

                                       ###